Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is a digital healthcare company in the medical device industry that has the potential for strong revenue growth and increasing profitability due to their innovative Zio monitoring system. The company has consistently beaten revenue estimates and raised guidance, highlighting the success of their core business and expanding into new market segments. Additionally, potential drivers such as international expansion, launch of new products, and operating leverage could provide further upside potential for the company. While there are potential risks such as competition and changes in reimbursement, the company's strong financial performance and strategic partnerships make them a favorable investment opportunity.

Bears say

iRhythm Holdings is facing potential challenges with growth in the future, as evidenced by only modest market share gains despite significant investments in research and development. Additionally, the company's impressive gross margin beat will not be sustainable in the long term, and further improvements in profitability may be slowed due to increased competition and regulatory issues with reimbursement. These factors could result in a bear case scenario with growth slowing to the low teens, making the stock overvalued at an EV/sales multiple of 5.5x our 2026 estimate.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $187, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $187, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.